GlassScriptPhysician profile
Malek Mushref
NPI 1619339124
$8,946.03
in general payments reported to CMS, 2019-2025
21 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $347 · 2023: $694 · 2024: $7,287 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,160 · Food and Beverage: $2,214 · Travel and Lodging: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,160.00 |
| Food and Beverage | $2,213.58 |
| Travel and Lodging | $1,084.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $5,375.96 | 2022-2025 | |
| Medtronic, INC. | $1,662.71 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $358.23 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $272.83 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $272.78 | 2021-2025 | Mounjaro, Baqsimi, Lyumjev |
| Insulet Corporation | $223.28 | 2021-2024 | Omnipod |
| Amgen INC. | $148.07 | 2022-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $105.33 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $98.87 | 2023-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $66.61 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $62.89 | 2024 | |
| Radius Health, INC. | $53.60 | 2023-2025 | Tymlos |
| Corcept Therapeutics | $40.90 | 2023-2024 | Korlym |
| Dexcom, INC. | $38.99 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.39 | 2024-2025 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.67 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $24.62 | 2024 | |
| Pfizer INC. | $22.87 | 2024 | |
| Beta Bionics, INC. | $22.18 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amneal Pharmaceuticals LLC | $16.07 | 2023 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $15.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malek Mushref listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.